Skip to content

LINDA PHARMA

Active
Private limited companyfounded 2025active for 1 yearLeopoldstadplein 16, 1040 Etterbeek, BelgiumKBO/BCE: BE 1025.098.275

From the official registers: KBO 1 annual account at the National Bank publications in the Belgian Official Gazette

Summary

The computed 12-month bankruptcy probability of LINDA PHARMA is 2.1% (moderate). The 2025 annual accounts show equity of €43,688 and a net result of €34,521. Its solvency ranks better than 36% of 22,726 sector peers (NACE 47, financial year 2025). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
LINDA PHARMAActiveChecked score 54/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 03-07-2025 Normal situation
Activity
Retail sale of pharmaceutical products NACE 47730
Establishment units
2.375.649.368 1040 Etterbeek, since 03-07-2025
2.376.914.625 1040 Etterbeek, since 03-07-2025
Financial year end
31 December
Peppol
Reachable since 25-12-2025
Company details

Board and ownership

Board
Board & ownership

Financial position

54 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
2.1%
Annual accounts 2025
Gross margin
€60,555
Turnover
≈ €290,000
estimated
Profit
€34,521
Equity
€43,688
Total assets
€258,710
Employees on 31-12-2025
1
  • 2025 accounts filed 27 days after the deadline
Filed on 27-08-2026
Financials
Score breakdownraises riskFounded in 2025Sector: Retail trade (NACE 47)Size: total assets €258,7102 establishment unitsShow the evidence

Checked score

Score 2025
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 49% of micro companies in retail trade (NACE 47)
Every signal that counts is listed under Signals.
Financial strength
Average
Solvency 42
equity 16.9% of total assets
Liquidity 38
short-term debt 47.3% · cash 9.0%
Profitability 85
return on assets 13.3%
Bankruptcy probability within 12 months
2.1% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,272 companies, NACE 47, micro)
Last 24 months 08-2026: 2.2%highest value 09-2026: 1.8%▼ -0.4 percentage points vs 08-2026lowest value 10-2026: 2.1%▲ +0.3 percentage points vs 09-2026 11-2026: 2.1%● unchanged vs 10-2026
Credit of up to €2,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.34, below the usual 1.5. Short-term debt is 47.3% and cash 9% of total assets. 83.1% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 33% of them on solvency, 35% on liquidity and 80% on profitability.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
raises risk
raises risk · Founded in 2025
Companies of this age fail more often than older ones. How much that weighs depends on the rest of the company's profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
raises risk · Size: total assets €258,710
Companies of this size fail more often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · 2 establishment units
KBO · seat and establishments
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 1 filing
Deviation from the deadline
2025
27 days late
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2025.
KBO publications

Key points

  • Positive: Higher net result than 82% of companies in retail tradesector median €5,089 · 22,707 companies €34,521 View

Comparable companies

These companies have the same main activity as LINDA PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €169,000 and €382,000, founded between 2023 and 2025.

CompanyTotal assetsGross margin
LINDA PHARMA Etterbeek€258,710€60,555
Apotheek Sophie Vandewynckele Eeklo€214,484€62,294
AVA-ROSE Jette€381,859€50,368
Astgen Leboeuf Sint-Lambrechts-Woluwe€378,915€79,684
PHARMACIE KLIPVELD Ukkel€168,665€64,720
Babay Pharma Sint-Joost-ten-Node€246,996€113,391
PHARMACIE V. PIROTTE Seraing€209,269€60,759
Full comparison

Documents

Annual accounts at the NBB

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about LINDA PHARMA
What is the company number of LINDA PHARMA?
The company number of LINDA PHARMA is 1025.098.275. The VAT number is the same number with BE in front: BE 1025.098.275.
Where is LINDA PHARMA based?
The registered office is at Leopoldstadplein 16, 1040 Etterbeek.Company details
What does LINDA PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of LINDA PHARMA?
The legal form of LINDA PHARMA is Private limited company (BV).
When was LINDA PHARMA founded?
LINDA PHARMA was founded on 03-07-2025.
Is LINDA PHARMA still active?
Yes, LINDA PHARMA is an active enterprise in the KBO register.
How many employees does LINDA PHARMA have?
LINDA PHARMA had an average of 0.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of LINDA PHARMA?
The turnover in financial year 2025 is ≈ €290,000. This figure is estimated from the gross margin of €60,555 and 44 comparable companies (NACE 477). It probably lies between €150,000 and €400,000.
Is LINDA PHARMA profitable?
In financial year 2025, LINDA PHARMA made a profit of €34,521.
Where can I find the annual accounts of LINDA PHARMA?
LINDA PHARMA filed 1 annual account with the National Bank of Belgium, for financial year 2025.Annual accounts at the National Bank

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See whether the workforce is growing and whether people stay.Employer check

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure